Mortality and Cost of XXXX after Vascular Surgery.

@entity1 @entity8 @entity740 @entity260 @entity810 @entity1011
BACKGROUND: Both @entity810 ( @entity810 ) and @entity740 ( @entity740 ) are common yet underappreciated risk factors for adverse perioperative outcomes. We hypothesize that @entity810 and @entity740 are associated with similar increases in 90-day mortality and cost in @entity1 undergoing major vascular surgery. METHODS: We used multivariable regression analyses to evaluate the associations between @entity810 and @entity740 and incremental 90-day mortality and hospital cost in a single-center cohort of 3646 adult @entity1 undergoing major vascular surgery. We defined @entity810 using Kidney Disease: Improving Global Outcomes criteria as change in @entity1011 >=  0.3 mg/dL or >=  50% increase from the reference value. @entity740 was determined from medical history. Regression models were adjusted for demographic and socioeconomic characteristics, comorbid conditions, surgery type, and @entity260 . RESULTS: The prevalence of @entity8 among vascular surgery @entity1 is high with 49% of @entity1 developing @entity810 during hospitalization and 17% presenting with @entity740 on admission. In risk-adjusted logistic regression analysis, perioperative @entity810 (odds ratio 2.2, 95% confidence interval 1.5-3.3) was the most significant predictor of 90-day mortality. The risk-adjusted average cost was significantly higher for @entity1 with any @entity8 . The incremental cost of having any @entity8 ranged from  9100 to  19,100, even after adjustment for underlying comorbidities and other @entity260 . CONCLUSIONS: @entity8 after major vascular surgery is associated with significant increases in 90-day mortality and cost with the highest risk observed among @entity1 with @entity810 regardless of previous @entity740 .
